[Clinical significance of testosterone and dihydrotestosterone metabolism in women].
Hyperandrogenism in women refers to both excess androgen production and clinical manifestations of androgen excess. Clinical evaluation of women with hyperandrogenism is complex. The synthesis and release of androgenic steroid in women are normal part of adrenal and ovarian steroidogenesis. One of the classic questions concerning androgenic disorders concerns the source of circulating androgens. Relative roles of adrenal and ovary vary greatly, both can be involved. The use of gonadal or adrenal steroid administration can sometimes be used to distinguish the source of androgen excess. In many cases of hyperandrogenism no laboratory diagnosis of adrenal and ovarian androgen overproduction can be made. These patients may have increased androgen sensitivity due to increased enzyme 5 alpha-reductase activity in the skin. To be active in the skin, testosterone (T) must be converted to dihydrotestosterone (DHT) by the 5 alpha-reductase. The increase in DHT production is a localized phenomenon and there is no generalized increase in enzyme activity in women with hyperandrogenism. DHT is rapidly converted to other steroid metabolites including androsteron, androstanediol and their glucuronide and sulfate conjugates. Although once thought to be specific for skin conversion of T to DTH these androgen conjugates reflect adrenal steroid production and metabolism. Antiandrogens (androgen receptor blockers) are the most effective therapeutic modalities of cutaneous hyperandrogenism. Clinical trials are in progress to determine efficacy of finasteride for the treatment of hirsutism and androgenetic alopecia. Finasteride is the first available medication of a new class of drugs that is an competitive inhibitor of 5 alpha-reductase and therefore should be beneficial for medical treatment of cutaneous hyperandrogenism.
Korsić
M
M
Zavod za endokrinologiju, dijabetes i bolesti metabolizma Klinike za unutarnje bolesti, KBC Rebro, Zagreb.
D000726:Androgen Antagonists / Q000627:therapeutic use; D013196:Dihydrotestosterone / Q000378:metabolism*; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000188:drug therapy / Q000378:metabolism*; D013739:Testosterone / Q000378:metabolism*
D000726:Androgen Antagonists; D013196:Dihydrotestosterone; D013739:Testosterone
Klinicko znacenje metabolizma testosterona i dihidrotestosterona u zena.